Found: 77
Select item for more details and to access through your institution.
Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor.
- Published in:
- EMBO Molecular Medicine, 2021, v. 13, n. 2, p. 1, doi. 10.15252/emmm.202012640
- By:
- Publication type:
- Article
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6526, doi. 10.3390/ijms22126526
- By:
- Publication type:
- Article
Novel insight into the role of clusterin on intraocular pressure regulation by modifying actin polymerization and extracellular matrix remodeling in the trabecular meshwork.
- Published in:
- Journal of Cellular Physiology, 2022, v. 237, n. 7, p. 3012, doi. 10.1002/jcp.30769
- By:
- Publication type:
- Article
C22:0- and C24:0-dihydroceramides Confer Mixed Cytotoxicity in T-Cell Acute Lymphoblastic Leukemia Cell Lines.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074768
- By:
- Publication type:
- Article
c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αv&beta3 and αv&beta5.
- Published in:
- PLoS ONE, 2012, v. 7, n. 8, p. 1, doi. 10.1371/journal.pone.0042291
- By:
- Publication type:
- Article
Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts.
- Published in:
- PLoS ONE, 2012, v. 7, n. 3, p. 1, doi. 10.1371/journal.pone.0033894
- By:
- Publication type:
- Article
Development of cell‐based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA‐PKcs and OCT4–MK2 interactions.
- Published in:
- Biotechnology & Bioengineering, 2021, v. 118, n. 5, p. 1987, doi. 10.1002/bit.27712
- By:
- Publication type:
- Article
A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 19, p. 6223, doi. 10.3390/jcm12196223
- By:
- Publication type:
- Article
Mechanism of Synergy of N-(4-Hydroxyphenyl) Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: McI-1 Inactivation.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 8, p. 580, doi. 10.1093/jnci/djn076
- By:
- Publication type:
- Article
Prion protein modulates endothelial to mesenchyme-like transition in trabecular meshwork cells: Implications for primary open angle glaucoma.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49482-6
- By:
- Publication type:
- Article
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 97, doi. 10.1007/s00280-023-04543-6
- By:
- Publication type:
- Article
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 4, p. 525, doi. 10.1007/s00280-020-04224-8
- By:
- Publication type:
- Article
DNA-PK as an Emerging Therapeutic Target in Cancer.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00635
- By:
- Publication type:
- Article
P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
- Published in:
- International Journal of Cancer, 2017, v. 141, n. 2, p. 405, doi. 10.1002/ijc.30706
- By:
- Publication type:
- Article
MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 5, p. 1, doi. 10.1038/s41419-020-2563-4
- By:
- Publication type:
- Article
Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.
- Published in:
- Cell Death & Disease, 2018, v. 9, n. 9, p. 1, doi. 10.1038/s41419-018-0964-4
- By:
- Publication type:
- Article
Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 6, p. 1106, doi. 10.1002/pbc.25329
- By:
- Publication type:
- Article
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 1, p. 91, doi. 10.1002/pbc.25201
- By:
- Publication type:
- Article
Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 11, p. 1972, doi. 10.1002/pbc.25175
- By:
- Publication type:
- Article
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1493, doi. 10.1002/pbc.25026
- By:
- Publication type:
- Article
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1486, doi. 10.1002/pbc.24989
- By:
- Publication type:
- Article
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 5, p. 922, doi. 10.1002/pbc.24800
- By:
- Publication type:
- Article
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 2, p. 245, doi. 10.1002/pbc.24724
- By:
- Publication type:
- Article
Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 1, p. 158, doi. 10.1002/pbc.24616
- By:
- Publication type:
- Article
An Optimized Liquid Chromatography–Mass Spectrometry Method for Ganglioside Analysis in Cell Lines.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 19, p. 1640, doi. 10.3390/cells13191640
- By:
- Publication type:
- Article
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
- Published in:
- British Journal of Pharmacology, 2014, v. 171, n. 23, p. 5330, doi. 10.1111/bph.12846
- By:
- Publication type:
- Article
Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
- Published in:
- Experimental Biology & Medicine, 2017, v. 242, n. 11, p. 1178, doi. 10.1177/1535370217706952
- By:
- Publication type:
- Article
Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.
- Published in:
- Experimental Biology & Medicine, 2014, v. 239, n. 10, p. 1390, doi. 10.1177/1535370214538745
- By:
- Publication type:
- Article
Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 3, p. 389, doi. 10.1111/j.1365-2141.2009.07631.x
- By:
- Publication type:
- Article
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 11, p. 1801, doi. 10.1002/pbc.24643
- By:
- Publication type:
- Article
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 11, p. 1860, doi. 10.1002/pbc.24647
- By:
- Publication type:
- Article
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 8, p. 1325, doi. 10.1002/pbc.24517
- By:
- Publication type:
- Article
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 7, p. E42, doi. 10.1002/pbc.24451
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 791, doi. 10.1002/pbc.24301
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 783, doi. 10.1002/pbc.24368
- By:
- Publication type:
- Article
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 4, p. 633, doi. 10.1002/pbc.24235
- By:
- Publication type:
- Article
Erratum: Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 August; 59(2):246-253
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 4, p. 772, doi. 10.1002/pbc.24291
- By:
- Publication type:
- Article
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 7, p. 1266, doi. 10.1002/pbc.24073
- By:
- Publication type:
- Article
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 1, p. 185, doi. 10.1002/pbc.23154
- By:
- Publication type:
- Article